As the Co-Founder and CEO of DBH, Holly began her journey into market access and value-based care over 15 years ago, with the advent of the HITECH Act in the US. Holly played a central role in developing the earliest electronic clinical quality measures (eCQMs) and clinical decision support tools (CDSS). Notably, Holly was recognized as the industry's first to directly embed a cost impact calculator within an EHR system. Her broad expertise, particularly in molecular diagnostics and AI/ML biotech, has been showcased on esteemed platforms such as HITLAB and WEDI. By 2022, her insightful podcasts garnered widespread industry attention, bolstering her stature as an influential thought leader.
Holly has collaborated widely, for example with The Joint Commission, CDC, National Institutes of Health, AMA and the largest global pharmaceutical and biotech companies. These engagements underscore her dedication to both transforming healthcare delivery and championing equitable, timely access to healthcare tools on a global scale.